Spironolactone 25mg

DRUG6 trials

Sponsors

Oregon Health and Science University, Columbia University, University Hospital, Caen, National University Hospital, Singapore, University Medical Center Goettingen

Conditions

Aldosterone BlockadeAortic Stenosis, SevereAtrial FibrillationCardiac SurgeryCongenital Heart DiseaseEndomyocardial FibrosisHeart Failure

Phase 2

Spironolactone in Adult Congenital Heart Disease

CompletedNCT01069510

Oregon Health and Science UniversityCongenital Heart Disease, Endomyocardial Fibrosis, Heart Failure

Start: 2010-02-28End: 2017-03-31Updated: 2019-08-21

Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance

CompletedNCT02585843

Columbia UniversityHeart Failure

Start: 2015-11-30End: 2017-03-31Updated: 2019-08-08

Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study

National University Hospital, SingaporeAtrial Fibrillation

Start: 2018-05-23End: 2022-05-31Target: 184Updated: 2020-03-31

Phase 3

Spironolactone and Perioperative Atrial Fibrillation Occurrence in Cardiac Surgery Patients.

University Hospital, CaenAldosterone Blockade, Atrial Fibrillation, Cardiac Surgery

Start: 2019-02-26End: 2021-09-30Target: 1500Updated: 2019-03-05

Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden

RecruitingNCT05230901

University Medical Center GoettingenAortic Stenosis, Severe

Start: 2022-02-23End: 2026-03-31Target: 300Updated: 2022-06-28

Phase 4

Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing

Active, not recruitingNCT07281014

Yale UniversityHeart Failure

Start: 2026-01-27End: 2027-08-01Updated: 2026-08-26

Related Papers

Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial.

2019-05-099 citations